Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;146(7):1829-1845.
doi: 10.1007/s00432-020-03236-4. Epub 2020 May 14.

Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

Andrey Soares  1   2 , Fernando Sabino Marques Monteiro  3   4 , Fernando Cotait Maluf  5   3   6 , Diogo Assed Bastos  7 , Denis Leonardo Jardim  7 , André Deeke Sasse  8 , Adriano Gonçalves E Silva  9 , André P Fay  10   11 , Diogo Augusto Rodrigues da Rosa  12 , Evanius Wierman  13 , Fabio Kater  6 , Fabio A Schutz  6 , Fernando Nunes Galvão de Oliveira  14 , Igor Alexandre Protzner Morbeck  15 , José Augusto Rinck Jr  16 , Karine Martins da Trindade  17   18 , Manuel Caitano Maia  19 , Vinicius Carrera Souza  20 , Deusdedit Cortez Vieira da Silva Neto  21 , Felipe de Almeida E Paula  22 , Fernando Korkes  5   23 , Gustavo Franco Carvalhal  10 , Lucas Nogueira  24 , Roni de Carvalho Fernandes  21   25 , Rodolfo Borges Dos Reis  26 , Wagner Eduardo Matheus  27 , Wilson Francisco Schreiner Busato Jr  28 , Walter Henriques da Costa  16   25   29 , Stênio de Cássio Zequi  16   29
Affiliations
Review

Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

Andrey Soares et al. J Cancer Res Clin Oncol. 2020 Jul.

Abstract

Purpose: The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to support the clinical decisions of physicians and other health professionals involved in the care of RCC patients.

Methods: Eighty questions addressing relevant advanced RCC treatments were previously formulated by a panel of experts. The voting panel comprised 26 specialists from the LACOG-GU/LARCG. Consensus was determined as 75% agreement. For questions with less than 75% agreement, a new discussion was held, and consensus was determined by the majority of votes after the second voting session.

Results: The recommendations were based on the highest level of scientific evidence or by the opinion of the RCC experts when no relevant research data were available.

Conclusion: This manuscript provides guidance for advanced RCC treatment according to the LACOG-GU/LARCG expert recommendations.

Keywords: Cytoreductive nephrectomy; Immunotherapy; Recommendations; Renal cell carcinoma; Treatment.

PubMed Disclaimer

Conflict of interest statement

Adriano Gonçalves e Silva—Speaker fee: Janssen, Pfizer, Bayer, AstraZeneca, Astellas, Pierre-Fabre, Sanofi, Roche, Merck Sharp & Dohme, and Bristol-Myers Squibb. Advisory board: Astellas, Janssen, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, and Sanofi. André Deeke Sasse—Honoraria: Janssen, Astellas, Roche, and Merck Sharp & Dohme. Advisory board: Janssen, Astellas, Roche, Merck Sharp & Dohme, and Bristol-Myers Squibb. Events sponsorship: Janssen and Roche. André P. Fay—Honoraria: Pfizer, Astellas, Bristol-Myers Squibb, Novartis, Roche, AstraZeneca, and Merck Sharp & Dohme. Advisory board: Janssen, Novartis, Roche, Pfizer, and Ipsen. Research funding: CAPES–CNPq, Bristol-Myers Squibb, AstraZeneca, Roche, Merck Sharp & Dohme, and Pfizer. Andrey Soares—Speaker fee: Janssen, Pfizer, Bayer, Novartis, AstraZeneca, Astellas, Pierre-Fabre, Merck-Serono, Sanofi, and Roche. Events sponsorship: AstraZeneca, Pfizer, Astellas, Bristol-Myers Squibb, Bayer, Roche, Janssen, Merck Serono, Sanofi, and Ipsen. Advisory board: Astellas, Janssen, Roche, Bayer, Lilly, AstraZeneca, Novartis, Merck Sharp & Dohme, and Bristol-Myers Squibb. Research funding: Bristol-Myers Squibb. Denis Leonardo Jardim—Speaker fee: Roche, Janssen, Astellas, Merck Sharp & Dohme, Bristol-Myers Squibb and Libbs. Advisory board: Janssen, Bristol-Myers Squibb and Libbs. Deusdedit Cortez Vieira da Silva Neto—Speaker fee: Janssen, Astellas, and Pfizer. Advisory board: Janssen. Diogo Assed Bastos—Research funding: Janssen, Astellas, Pfizer, and Merck Sharp & Dohme. Honoraria/advisory board: Janssen, Astellas, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Pfizer, Novartis, and Bayer. Diogo Augusto Rodrigues da Rosa—Research funding: Roche, Bristol-Myers Squibb, Janssen, Lilly, AstraZeneca, Merck, and Merck Sharp & Dohme. Speaker fee: Janssen, Pfizer, AstraZeneca, Astellas, Roche, Amgen, Dr Reddy's, and Merck Sharp & Dohme. Events sponsorship: Janssen, AstraZeneca, Astellas, Bristol-Myers Squibb, Bayer, Roche, Janssen, and Ipsen. Advisory board: Janssen, Bayer, and AstraZeneca. Evanius Wierman—Honoraria: Janssen and Libbs. Advisory board: Janssen. Fabio Kater—Speaker fee: Janssen, Roche, Amgen, Merck Sharp & Dohme, AstraZeneca, and Astellas. Events sponsorship: Roche and Janssen. Fabio A. Schutz—Advisory board: Bristol-Myers Squibb, Merck Sharp & Dohme, Ipsen, and Pfizer. Speaker's bureau: Roche, Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Janssen, and Astellas. Felipe de Almeida e Paula—None. Fernando Cotait Maluf—Research funding: Roche, Bristol-Myers Squibb, Novartis, and Janssen. Speaker fee: Sanofi, Novartis, Bayer, Janssen, Astellas, Bristol-Myers Squibb, and Pfizer. Advisory board: Sanofi, Bayer, Janssen, Astellas, Novartis, and Roche. Fernando Korkes—None. Fernando Nunes Galvão de Oliveira—Speaker fee: Astellas, Janssen, Merck Sharp & Dohme, Bayer, Roche, AstraZeneca, and Libbs. Advisory board: Merck Sharp & Dohme, Janssen, and Ferring. Fernando Sabino Marques Monteiro—Speaker fee and advisory board: Bristol-Myers Squibb. Gustavo Franco Carvalhal—None. Igor Alexandre Protzner Morbeck—Research funding: Astellas. Honoraria/advisory board: Janssen, Astellas, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Pfizer, Novartis and Bayer. José Augusto Rinck Júnior—Speaker fee/events sponsorship: Pfizer, Astellas, Bristol-Myers Squibb, Merck Sharp & Dohme, Bayer, Roche, Janssen, and Aché. Karine Martins da Trindade—Research funding: Roche, Bristol-Myers Squibb, and Merck Sharp & Dohme. Speaker fee: Janssen, AstraZeneca, Astellas, Bristol-Myers Squibb, Roche, Pfizer, and Merck Serono. Events sponsorship: Janssen, Astellas, Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, Astellas, Merck Serono, Sanofi, and Novartis. Advisory board: Janssen, Roche, and Bristol-Myers Squibb. Lucas Nogueira—Speaker fee: Janssen, Pfizer, Bayer, Astellas, Pierre-Fabre, Roche, and Merck Sharp & Dohme. Events sponsorship: Astellas, Bayer, and Janssen. Advisory board: Astellas, Janssen, and Merck Sharp & Dohme. Manuel Caitano Maia—Speaker fee: Pfizer. Events sponsorship: Pfizer, Astellas, Bristol-Myers Squibb, Bayer, Roche, Janssen, and Libbs. Roni de Carvalho Fernandes—Events sponsorship: Astellas, Janssen, and Handle/Cook. Speaker fee: Janssen and Aché. Advisory board: Janssen. Rodolfo Borges dos Reis—Speaker fee: Janssen and AstraZeneca. Advisory board: Janssen and Astellas. Research funding: AstraZeneca. Events sponsorship: Janssen, Pfizer, Astellas, and Roche. Stênio de Cássio Zequi—Speaker fee: Bristol-Myers Squibb, Pfizer and AstraZeneca. Research funding: Merck Sharp & Dohme. Events sponsorship: Astellas. Vinicius Carrera Souza—Research funding: Bristol-Myers Squibb and Janssen. Speaker fee: Bayer, Janssen, Novartis, AstraZeneca, and Merck Sharp & Dohme. Advisory board: Roche and Janssen. Wagner Eduardo Matheus—Speaker fee: Astellas, Janssen, Zodiac, AstraZeneca, and Aché. Events sponsorship: Astellas, Zodiac, Janssen, and AstraZeneca. Walter Henriques da Costa—None. Wilson Francisco Schreiner Busato Jr—None.

References

    1. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663–670 - PubMed
    1. ANVISA, Agência Nacional de Vigilância Sanitária (2019) Resolução-re nº 2.282, de 16 de agosto de 2019. Diário Oficial da União. http://www.in.gov.br/web/dou/-/resolucao-re-n-2.282-de-16-de-agosto-de-2.... Accessed 31 Jan 2020
    1. Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G (2019) The role of metastasectomy in advanced renal cell carcinoma. Expert Rev Anticancer Ther 19(7):603–611 - PubMed
    1. Armstrong AJ, Broderick S, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, Halabi S, George DJ (2015) Final clinical results of a randomized phase II international trial of everolimus vs sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol 2015:33
    1. Atkins MB, McDermott DF, Powles T, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth JD, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Qiu J, Huseni MA, Schiff C, Escudier BJ (2017) IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 2017:35